— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…
January 13, 2026 07:05 ET | Source: Sight Sciences, Inc. MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight…
January 13, 2026 07:05 ET | Source: Treace Medical Concepts, Inc. PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) --…
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28…
January 12, 2026 10:30 ET | Source: BridgeBio Pharma, Inc. - Preliminary unaudited Q4 and Full Year 2025 net Attruby® product…
Knoxville, TN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), a leading AI technology company delivering multimodal…
January 11, 2026 13:00 ET | Source: Krystal Biotech, Inc. Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to…
January 11, 2026 09:30 ET | Source: RxSight, Inc. ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…